Epithelial ovarian cancer: focus on targeted therapy.
Ovarian cancer remains the leading cause of gynecological cancer-related mortality in the Western World despite the advances in surgical techniques and chemotherapy regimens over the past three decades. Although response rates and complete responses in advanced disease are >80% and 40-60%, respectively, after first-line treatment with carboplatin and paclitaxel, most of the patients will eventually relapse with a median progression-free survival of 18 months. Currently, research efforts have improved our understanding on the molecular biology of ovarian cancer and novel targeted treatment strategies are likely to contribute to the management of the disease and give the chance to an individualized therapeutic approach.
Pliarchopoulou
Kyriaki
K
Second Department of Internal Medicine, Propaedeutic Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, Greece. kpliarch@otenet.gr
Pectasides
Dimitrios
D
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D006801:Humans; D058990:Molecular Targeted Therapy; D009375:Neoplasms, Glandular and Epithelial / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000037:antagonists & inhibitors / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D040262:Receptors, Vascular Endothelial Growth Factor; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A; C494929:PTEN protein, human